With data that a pCR achieved with less intense chemotherapy may have the same excellent outcomes as pCR attained with more chemotherapy37, this approach is being evaluated in patients with HER2+ breast cancer (CompassHER2 pCR; NCT04266249) and merits investigation in gBRCAm carriers. The gene discussed is ERBB2; the disease is breast carcinoma.